Yes, this is not new information. It was pretty thoroughly discussed on this board over the past few months. Several contributors also spent a lot of effort breaking out how much (or how little, in this case) Hims would be affected by the expiration of the special shortage status given to wegovy - type drugs.
The upshot, at least in my view, was that Hims is in no way reliant on weight loss meds, has a very solid strategy, and has been consistently executing. The stock price, however, is bouncy like few others. It may not be your style